Recommendations for evaluating the safety of medicinal products containing nanoparticles
Abstract
Recommendations for preclinical safety assessment of medicinal products containing nanoparticles are presented. The recommendations provide conditions for research acute and chronic toxicity of nanotherapeutics, methods for their quantitative and qualitative assessments.
About the Authors
R. N. Alyautdin
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
B. K. Romanov
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Bleeker EA, de Jong WH, Geertsma RE, et al. Considerations on the EU definition of a n anomaterial: science to support policy making. Regul Toxicol Pharmacol. 2013;65(1):119–125.
2. Chang HI, Yeh M-K. Clinical development of li posome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
3. Kessler R. Engineered n anoparticles in consumer products: understanding a new ingredient. Environ Health Perspect. 2011;119(3):a120–a125.
4. Vega-Villa KR, Takemoto JK, Yáñ ez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of n anocarrier systems. Adv Drug Deliv Rev. 2008;60(8):929−938.
5. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1–27.
6. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging. 2010;9(6): 291–310.
7. Wick P, Manser P, Limbach LK, et al. The degree and kind of agglomeration affect carbon n anotube cytotoxicity. Toxicol Lett. 2007;168(2):121–131.
8. SZiemba B, Matuszko G, Bryszewska M, Klajnert B. Influence of dendrimers on red blood cells. Cell Mol Biol Lett. 2012;17(1):21–35.
9. Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol Sci. 2008;101(1):4–21.
10. Devalapally H, Chakilam A, Amiji MM. Role of n anotechnology in pharmaceutical product development. J Pharm Sci. 2007;96(10): 2547–2565.
11. Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered n anoparticles for drug delivery. J Control Release. 2013;166(2):182–194.
12. Petros RA, DeSimone JM. Strategies in the design of n anoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–62.
13. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based n anocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–14.
14. Oberdörster G, Mayn ard A, Don aldson K, et al. Princi ples for characterizing the potential human health effects from exposure to n anomaterials: elements of a screening strategy. Part Fibre Toxicol. 2005;2.
15. NanoMarkets. Доступно на nanomarkets.net/images/uploads/ NMThinFilmPrintedBatteries_08.pdf Файл PDF.
16. Kermanizadeh A, Gaiser BK, Johnston H, D et al. Toxicological effect of engineered n anomaterials on the liver. Brit. J. Pharmacol. 2014, 171: 3980-3987.
17. Kettiger H, Schi panski A, Wick P .Engineered n anomaterial uptake and tissue distribution: from cell to organism. Intern ation al Journ al of Nanomedicine. 2013, 8: 3255–3269.
18. Руководство по проведению доклинических исследований лекарственных средств. Особенности изучения общетоксического действия лекарственных средств и средств медицинского назначения, содержащих наночастицы.2012. Издание ФГБУ «НЦЭМСП».
19. Fleischer CC, Payne CK. Nanoparticle surface charge mediates the cellular receptors used by protein-n anoparticle complexes. J Phys Chem B. 2012;116(30):8901– 8907.
20. Asha Rani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver n anoparticles in human cells. ACS Nano. 2009;3(2):279–290.
21. Shim J, Seok Kang H, Park WS, et al. Transdermal delivery of mixnoxidil with block copolymer n anoparticles. J Control Release. 2004;97(3):477–484.
22. Aggarwal N, Goindi S. Preparation and in vivo evaluation of solid li pid n anoparticles of griseofulvin for dermal use. J Biomed Nanotechnol. 2013;9(4):564–576.
23. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered n anomaterials. Nat Nanotechnol. 2007;2(8):469–478.
24. Gasser M, Rothen-Rutishauser B, Krug HF, et al. The adsorption of biomolecules to multi-walled carbon n anotubes is influenced by both pulmon ary surfactant li pids and surface chemistry. J Nanobiotechnology. 2010;8:31.
25. Gessner A, Waicz R, Lieske A et al. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm. 2000;196(2):245–249.
26. Downs TR, Crosby ME, Hu T, et al.(2012). Silica n anoparticles administrated at the maximum tolerated dose induce genotoxic effects through an inflammatory reaction while gold n anoparticles do not. Mutat Res 745: 38–50.
27. Alyautdin RN, Romanov BK, Merculov VA. The distribution of fullerene n anoparticles in the body in preclinical studies. Safety and Risk of Pharmacotherapy.2015;(3): 24-31.
28. Dragoni S, Franco G, Regoli M, Bracciali M et al. (2012). Gold n anoparticles uptake and cytotoxicity assessed on rat liver precision cut slices. Toxicol Sci 128: 186–197.
29. Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M et al. (2009). Biodistribution of gold n anoparticles inmouse lung following intratracheal instillation. Chem Cent J 3: 16. doi: 10.1186/1752-153X-3-16.
30. Fadeel B (2012). Clear and present danger? Engineered n anoparticles and the immune response. Swiss Med Wkly 142: w13609. doi: 10.4414/smw.2012.13609.
31. Kim S, Choi JE, Choi J et al. (2009).Oxidative stress-dependant toxicity of silver n anoparticles in human hepatoma cells. Toxicol in Vitro 23: 1076–1084.
Review
For citations:
Alyautdin R.N., Romanov B.K. Recommendations for evaluating the safety of medicinal products containing nanoparticles. Safety and Risk of Pharmacotherapy. 2015;(4):10-22. (In Russ.)
Views:
940
Email this article 